Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA PALB2. These kits offer efficient, targeted, and confident analysis of genes associated…
Devyser's Deputy CEO and founder Ulf Klangby will leave his position within the company for an advisory role as a consultant as of July 1, 2023.
Ulf Klangby will leave his operational…
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted regulatory approval in Canada. Devyser already has a contract with Canada’s Héma-Québec to…
“The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product. After the end of the quarter, we were also able to…
Devyser is today announcing that the company's clinical testing laboratory in Roswell in Atlanta, Georgia, has received CLIA certification. This certification allows the Devyser US lab to…
On Tuesday May 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q1 2023 report (which will have been published earlier on May 9, at 07.30 CET). The…
Devyser has been awarded the Swecare Export Award 2023. The prize is awarded to companies that "with creativity, commitment and scope put Swedish innovation in health and healthcare on…
Collaboration and distribution agreement with Thermo Fisher Scientific.
Thermo Fisher Scientific obtains exclusive rights to commercialize Devyser’s post-transplant monitoring…
Devyser´s annual report 2022 has today been published on the company´s website.
The report is available on: https://investors.devyser.com/en/reports-presentations
The financial year…
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified product. Devyser Compact is a rapid genetic test for prenatal chromosome testing and the…
